A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.

Safety and Weight Reduction of Sibutramine in the Treatment of Thai Obese and Overweight Subjects

The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.

Inclusion Criteria:

• Subject has nutritional obesity and BMI >30 kg/m

Exclusion Criteria:

• Type 1 or type 2 diabetes mellitus

• Inadequately controlled hypertension

• History of Gilles de la Tourette's Syndrome.

• Use of any MAOIs, SSRIs, amino acids, antimigraine drugs, opioids

• Hypothyroidism or hyperthyroidism.

• History of:

  • benign prostatic hyperplasia
  • neurological disorders
  • psychiatric illness
  • severe renal or hepatic impairments
  • narrow-angle glaucoma

• History of cardiovascular disease or cerebrovascular disease

• Persistent tachycardia at rest

• Pulmonary hypertension

• Phaeochromocytoma